Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 74   

Articles published

PSTI 2.72 -0.14 (-4.90%)
price chart
United Therapeutics Advances to Second Cohort in Phase I Trial of Pluristem's ...
Pluristem Therapeutics Inc. PSTI, -4.90% (tase:PLTR), a leading developer of placenta-based cell therapy products, announced today that its licensee, United Therapeutics Corporation, has completed the dosing of the first cohort of patients in its Phase ...
Phase I Trial of Pluristem's PLX-PAD Cells for Pulmonary Arterial ...  Pulmonary Hypertension News
Related articles »  
Insider Buying: Pluristem Therapeutics COO Buys 11000 Shares of Stock (PSTI)
Pluristem Therapeutics Inc (NASDAQ:PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.
Pluristem Therapeutics Earns Outperform Rating from Analysts at Oppenheimer ...  Mideast Time
Market Movers: National Bank of Greece (NYSE:NBG), Cisco Systems (NASDAQ ...  WallStreet Scope
Related articles »  
Pluristem Therapeutics Coverage Initiated by Analysts at Oppenheimer (PSTI)
Pluristem Therapeutics Inc. logo Oppenheimer began coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a research note released on Monday.
Oppenheimer Initiates Coverage on Pluristem Therapeutics (PSTI)  sleekmoney
Biotech Insider Buying : Halozyme Therapeutics (NASDAQ:HALO), RXi ...  WallStreet Scope
Related articles »  
H.C. Wainwright Starts Pluristem Therapeutics (PSTI) at Buy
H.C. Wainwright initiates coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and a price target of $4.00. Analyst Reni Benjamin said, "We are initiating coverage of Pluristem Therapeutics, Inc. with a Buy rating and a 12-month target ...
Pluristem Therapeutics CEO Zami Aberman Purchases 15000 Shares (PSTI)
Pluristem Therapeutics logo Pluristem Therapeutics (NASDAQ:PSTI) CEO Zami Aberman acquired 15,000 shares of the company's stock on the open market in a transaction dated Tuesday, September 16th. The stock was purchased at an average price of ...
Pluristem Therapeutics CEO Zami Aberman Buys 15000 Shares (PSTI)  Mideast Time
Related articles »  
Coverage Initiation Report Focuses on Pluristem Therapeutics
The company's proprietary 3-dimensional cell growth methods and manufacturing facility have an estimated $1 billion worth of production capacity per year, setting PSTI apart from the rest of the cell therapy market.
Related articles »  
Pluristem Therapeutics Receives New Coverage from Analysts at HC ...
Pluristem Therapeutics Inc. logo HC Wainwright started coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a research report sent to investors on Monday morning.
Pluristem to Deliver Scientific Presentations at 3rd International Placenta ...  NASDAQ
Related articles »  
Pluristem Therapeutics Now Covered by Oppenheimer (PSTI)
Pluristem Therapeutics Inc. logo Investment analysts at Oppenheimer initiated coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a note issued to investors on Monday.
Pluristem Therapeutics COO Yaky Yanay Purchases 11000 Shares (PSTI)  Intercooler
Related articles »  
Pluristem Therapeutics Given New $3.00 Price Target at Jefferies Group (PSTI)
Pluristem Therapeutics Inc. logo Pluristem Therapeutics (NASDAQ:PSTI) had its price objective decreased by Jefferies Group from $3.50 to $3.00 in a report released on Monday.
Pluristem Therapeutics PT Lowered to $3.00 (PSTI)  sleekmoney
What's Hot Today: Avago Technologies Limited (NASDAQ:AVGO), General ...  WallStreet Scope
Related articles »  
Pluristem Therapeutics COO Buys $32450 in Stock (PSTI)
Pluristem Therapeutics (NASDAQ:PSTI) opened at 3.04 on Thursday. Pluristem Therapeutics has a one year low of $2.58 and a one year high of $4.63.
Biotech Insider Buying : Exelixis (NASDAQ:EXEL), La Jolla Pharmaceutical Co ...  WallStreet Scope
Related articles »